Investors.
Investors.
CSE: MOOD | FSE: VU7 | PINK: DOSEF
Doseology is a performance-driven innovation company at the intersection of biotechnology and advanced delivery systems, engineering precision-formulated oral stimulants that optimize energy, focus, and cognitive performance. Through science-backed research and cutting-edge formulation technologies, the Company is pioneering next-generation performance solutions that empower consumers to perform at their peak.
_____________________________________
For business, media and investor inquiries please contact:
hello@doseology.com
Team
Christopher Cherry
INTERIM CEO, CFO
Christopher Cherry brings over 15 years of corporate accounting and audit experience. His previous roles include Director, CFO, and Secretary for several public companies across a broad range of sectors. Christopher, a Chartered Accountant since February 2009, has specialized in auditing junior public companies and IPOs during his tenure at KPMG and Davidson and Co. LLP in Vancouver.
Daniel Vice
DIRECTOR, CO-FOUNDER
Daniel Vice brings advanced knowledge in pharmacotherapeutics, neuroscience, and psychiatry to Doseology. He is passionate about an integrative approach to mental health, including evidence-based treatments with the goal of achieving the best health outcomes for individuals. Daniel is a nurse and received his Master’s Degree in Nursing from Johns Hopkins University. Daniel was recently featured in the Policy 2050 report “Innovations in Dietary Supplements."
Scott Reeves
DIRECTOR, CORPORATE COUNSEL
Scott Reeves has 20+ years focused on securities, corporate finance, M&A and commercial transactions. In addition to serving on several TSX and TSX Venture exchange across multiple industries, Scott is also a partner at Tingle Merrett LLP in Calgary. He is Past Chairman and Member of the Canadian Bar Association, Calgary Bar and Law Society of Alberta.